Barclays PLC Purchases 70,255 Shares of Codexis, Inc. (NASDAQ:CDXS)

Barclays PLC increased its holdings in Codexis, Inc. (NASDAQ:CDXS) by 51.1% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 207,628 shares of the biotechnology company’s stock after acquiring an additional 70,255 shares during the period. Barclays PLC owned about 0.26% of Codexis worth $640,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently modified their holdings of the company. FMR LLC boosted its position in Codexis by 1.2% in the third quarter. FMR LLC now owns 4,497,090 shares of the biotechnology company’s stock worth $13,851,000 after purchasing an additional 51,822 shares during the last quarter. Geode Capital Management LLC boosted its holdings in shares of Codexis by 0.7% in the 3rd quarter. Geode Capital Management LLC now owns 1,644,039 shares of the biotechnology company’s stock worth $5,065,000 after buying an additional 11,082 shares during the last quarter. State Street Corp grew its position in Codexis by 2.7% during the third quarter. State Street Corp now owns 1,551,411 shares of the biotechnology company’s stock valued at $4,778,000 after buying an additional 41,480 shares during the period. Assenagon Asset Management S.A. increased its holdings in Codexis by 23.4% during the third quarter. Assenagon Asset Management S.A. now owns 1,103,442 shares of the biotechnology company’s stock worth $3,399,000 after buying an additional 209,207 shares during the last quarter. Finally, abrdn plc raised its position in Codexis by 62.5% in the third quarter. abrdn plc now owns 800,410 shares of the biotechnology company’s stock worth $2,465,000 after acquiring an additional 307,762 shares during the period. 78.54% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research firms have recently weighed in on CDXS. Cantor Fitzgerald reissued an “overweight” rating and set a $11.00 target price on shares of Codexis in a research report on Friday, November 22nd. Benchmark reissued a “hold” rating on shares of Codexis in a report on Monday, November 4th.

Codexis Price Performance

CDXS opened at $4.92 on Friday. The firm has a 50-day moving average price of $4.77 and a 200-day moving average price of $3.71. Codexis, Inc. has a twelve month low of $2.53 and a twelve month high of $6.08. The company has a quick ratio of 3.15, a current ratio of 3.21 and a debt-to-equity ratio of 0.39. The company has a market capitalization of $400.39 million, a price-to-earnings ratio of -5.66 and a beta of 2.13.

Codexis (NASDAQ:CDXS) last released its quarterly earnings data on Thursday, October 31st. The biotechnology company reported ($0.29) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.04). Codexis had a negative net margin of 96.35% and a negative return on equity of 71.56%. The business had revenue of $12.83 million during the quarter, compared to analysts’ expectations of $11.64 million. During the same quarter in the prior year, the firm posted ($0.26) earnings per share. Equities analysts expect that Codexis, Inc. will post -0.77 EPS for the current year.

Codexis Company Profile

Codexis, Inc discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes.